ArticleClinical and molecular hepatology2019

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.

Christian Mölleken et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.